ORBi: Baron Frédéric - Value of infliximab (Remicade) in patients with low-risk myelodysplastic syndrome. Final results of a randomized phase II trial (EORTC trial 06023) of the EORTC Leukemia Group

Reference : Value of infliximab (Remicade) in patients with low-risk myelodysplastic syndrome. Final...


	Document type :	Scientific journals : Article
	Discipline(s) :	Human health sciences : Hematology
	To cite this reference:	http://hdl.handle.net/2268/112511

Title :	Value of infliximab (Remicade) in patients with low-risk myelodysplastic syndrome. Final results of a randomized phase II trial (EORTC trial 06023) of the EORTC Leukemia Group
Language :	English
Author, co-author :	Baron, Frédéric [Université de Liège - ULg > > GIGA-R : Hématologie >]
	Suciu, Stefan [EORTC Headquarters (Brussels) > >]
	Amadori, Sergio [Tor Vergata University Hospital (Rome, Italy) > >]
	Muus, Petra [Radboud University Nijmegen Medical Centre (The Netherlands) > >]
	Zwierzina, Heinz [Medizinische Universitätsklinik (Innsbruck, Austria) > >]
	Denzlinger, Claudio [Medical Clinic III (Stuttgart, Germany) > >]
	Delforge, Michel [University Hospital Gasthuisberg (Leuven, Belgium) > >]
	Thyss, Antoine [Centre Antoine-Lacassagne (Nice, France) > >]
	Selleslag, Dominik [Algemeen Academisch Ziekenhuis St Jan (Bruges-Oostende, Belgium) > >]
	Indrak, Karel [University Hospital Olomouc (Czech Republic) > >]
	Ossenkoppele, Geert [Vrije Universiteit Medical Centre (Amsterdam, The Netherlands) > >]
	De Witte, Theo [Medizinische Universitätsklinik (Innsbruck, Austria) > >]
Publication date :	2012
Journal title :	Haematologia
Publisher :	VSP
Volume :	97
Issue/season :	4
Pages :	529–533
Audience :	International
ISSN :	0017-6559
City :	Utrecht
Country :	The Netherlands
Keywords :	[en] infliximab ; tumor necrosis factor alpha ; MDS ; myelodysplastic syndrome ; phase II ; randomized
Abstract :	[en] Tumor-necrosis factor alpha activity has been correlated to ineffective erythropoiesis in lower risk myelodysplastic syndromes. Infliximab (Remicade) is an anti-tumor-necrosis factor alpha chimeric antibody that is used in the treatment of patients with heumatoid arthritis or Crohn's disease. Forty-six patients with myelodysplastic syndromes and a relatively low risk of developing acute leukemia were included in a randomized phase II study assessing the therapeutic activity of two dosages of infliximab administration (3 mg/kg versus 5 mg/kg). The primary endpoint was the response rate. Responses were observed in 3 of 22 patients (13.1%) randomized to the 3 mg/kg arm, versus 0 of 21 patients randomized in the 5 mg/kg arm. According to the statistical design of the current study, neither of the two infliximab dose schedules tested showed sufficient activity as a single agent in this cohort of unselected patients with early myelodysplastic syndrome.
Permalink :	http://hdl.handle.net/2268/112511
DOI :	10.3324/haematol.2011.044347

File(s) associated to this reference

Fulltext file(s):

	File	Commentary	Version	Size	Access
Open access	Remicade_EORTC_Haematologica2012.pdf		Publisher postprint	363.4 kB	View/Open

All documents in ORBi are protected by a user license.

Dspace v1.5